HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Bioscience, Inc. (NASDAQ: HBIO) announced today that its Board of Directors has authorized the repurchase by the Company of up to $10 million of its common stock in the open market or through privately negotiated transactions over the next 24 months. Under the program, shares may be repurchased from time to time and in such amounts as market conditions warrant, subject to regulatory considerations and any applicable contractual restrictions.
